# AbbVie Inc. (ABBV) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $256.46, market value $453.2 billion.

## Valuation
- **P/E (trailing): 72.4×** (5-yr avg 51.1×, 3-yr avg 72.2×). AbbVie Inc. trades at 72.4× trailing earnings, well above its own five-year average of 51.1×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 15.8×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 7.0×**. Each dollar of revenue is priced at 7.0×.
- **Free-cash-flow yield: 4.0%** (5-yr avg 8.0%). Free cash flow equals 4.0% of the market value, below its five-year average of 8.0%, so the shares are pricier on cash than usual.
- **Earnings yield: 1.4%**. The inverse of the P/E: 1.4% of the price is earned each year.

## Profitability
- **Operating margin: 26.2%**. 26.2% of revenue is left after running the business, an exceptional level.
- **Net margin: 6.9%**. 6.9% of each dollar of sales reaches the bottom line.
- **Return on equity: -129.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 22.8%**. Return on all capital, debt included, is 22.8%: comfortably above what that capital costs.
- **Return on assets: 4.7%**. Each dollar of assets produces 4.7% of profit.

## Growth
- **Revenue growth (1 yr): 8.6%** (3-yr 1.8%/yr, 5-yr 6.0%/yr). Revenue grew 8.6% over the last year, against 6.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -1.3%** (3-yr -29.1%/yr, 5-yr -2.8%/yr). Earnings per share fell 1.3%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -9.8%/yr**. Free cash flow has compounded at -9.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.70%** ($6.83 per share, trailing). AbbVie Inc. yields 2.70%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 276%** (66% of free cash flow). The dividend exceeds earnings (276% payout), though free cash flow still covers it.
- **Consecutive years of increases: 13**. 13 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 6.8%/yr** (1-yr 5.8%). The dividend has grown 6.8% a year over five years.

## Analyst view
- **Analyst consensus: buy** (29 analysts). 29 analysts cover AbbVie Inc.; the consensus is buy, with an average price target of $276.59 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 24.1%** (YTD 14.9%, 3-mo 13.7%). The shares are up 24.1% over twelve months including dividends.
- **From 52-week high: -4.1%** (34.4% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): -0.07** (volatility 27%). Beta of -0.07 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABBV · Page: https://foliofundamentals.com/stocks/abbv

Not investment advice.